Kinetic Characteristics of Neutralizing Antibody Responses Vary among Patients with COVID-19.
- Author:
Ling Hua LI
1
;
Hong Wei TU
2
;
Dan LIANG
2
;
Chun Yan WEN
1
;
An An LI
3
;
Wei Yin LIN
1
;
Ke Qi HU
3
;
Wen Shan HONG
4
;
Yue Ping LI
1
;
Juan SU
2
;
San Tao ZHAO
1
;
Wei LI
2
;
Run Yu YUAN
2
;
Ping Ping ZHOU
2
;
Feng Yu HU
1
;
Xiao Ping TANG
1
;
Chang Wen KE
2
;
Bi Xia KE
2
;
Wei Ping CAI
1
Author Information
- Publication Type:Journal Article
- Keywords: Kinetics; Neutralizing antibody; SARS-CoV-2; Sex
- MeSH: Adult; Aged; Aged, 80 and over; Antibodies, Neutralizing/immunology*; Antibodies, Viral/immunology*; COVID-19/immunology*; Female; Humans; Kinetics; Male; Middle Aged; Neutralization Tests; SARS-CoV-2
- From: Biomedical and Environmental Sciences 2021;34(12):976-983
- CountryChina
- Language:English
-
Abstract:
Objective:The coronavirus disease 2019 (COVID-19) pandemic continues to present a major challenge to public health. Vaccine development requires an understanding of the kinetics of neutralizing antibody (NAb) responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Methods:In total, 605 serum samples from 125 COVID-19 patients (from January 1 to March 14, 2020) varying in age, sex, severity of symptoms, and presence of underlying diseases were collected, and antibody titers were measured using a micro-neutralization assay with wild-type SARS-CoV-2.
Results:NAbs were detectable approximately 10 days post-onset (dpo) of symptoms and peaked at approximately 20 dpo. The NAb levels were slightly higher in young males and severe cases, while no significant difference was observed for the other classifications. In follow-up cases, the NAb titer had increased or stabilized in 18 cases, whereas it had decreased in 26 cases, and in one case NAbs were undetectable at the end of our observation. Although a decreasing trend in NAb titer was observed in many cases, the NAb level was generally still protective.
Conclusion:We demonstrated that NAb levels vary among all categories of COVID-19 patients. Long-term studies are needed to determine the longevity and protective efficiency of NAbs induced by SARS-CoV-2.
